Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

This article was originally published in PharmAsia News

Executive Summary

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.


Related Content

Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity
Pfizer Nutrition Continues Launches Despite Divestment Possibility
Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition
Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth
China Passes Food Safety Law Following Melamine Infant Formula Disasters
Insider Analysis From Sidley Austin LLP: Getting Ready For China’s Anti-Monopoly Law


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts